12 PENNS TRAIL, NEWTOWN, PA
Provides Business Highlights and Reports Q1 2026 Financial Results
Reports Full Year 2025 Results and Provides Business Highlights
Announces Up to $60 Million Private Placement Financing
Traws Pharma Updates on Ratutrelvir Study and Tivoxavir for Influenza
Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
Traws Pharma Files IND for Influenza, Updates on Ratutrelvir COVID-19 Study
Other Events
Executive Compensation Approved - Options and RSUs Granted
Q1
FY 2025
Notice of Late Filing for Annual Report
Q3
Q2
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
PRE 14A
Additional Proxy Materials
Definitive Proxy Statement
PRER14A
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership